660:
Nakazawa, Tsutomu; Murakami, Toshiharu; Natsume, Atsushi; Nishimura, Fumihiko; Morimoto, Takayuki; Matsuda, Ryosuke; Nakamura, Mitsutoshi; Yamada, Shuichi; Nakagawa, Ichiro; Park, Young-Soo; Motoyama, Yasushi; Tsujimura, Takahiro; Wakabayashi, Toshihiko; Nakase, Hiroyuki (2020-06-01).
602:
Stikvoort, Arwen; van der Schans, Jort; Sarkar, Subhashis; Poels, Renée; Ruiter, Ruud; Naik, Jyoti; Yuan, Huipin; de Bruijn, Joost D.; van de Donk, Niels W. C. J.; Zweegman, Sonja; Themeli, Maria; Groen, Richard; O’Dwyer, Michael; Mutis, Tuna (July 2021).
718:"A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line"
605:"CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma"
604:
355:
163:
319:
and their production is expensive and have to be personalized for each patient. So, several research groups have investigated the possibility of
39:
663:"KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells"
38:. The KHYG-1 cell line was established in 1997 in the laboratory of M Yagita in the department of Clinical Immunology and Haematology,
386:"A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation"
439:
Suck, Garnet; Branch, Donald R.; Smyth, Mark J.; Miller, Richard G.; Vergidis, Joanna; Fahim, Soad; Keating, Armand (October 2005).
336:
58:, for 18 months after isolation and its doubling time is around 24-48h. The ability to proliferate was retained even after
127:
51:
791:
384:
Yagita, M.; Huang, C. L.; Umehara, H.; Matsuo, Y.; Tabata, R.; Miyake, M.; Konaka, Y.; Takatsuki, K. (May 2000).
316:
490:"Irradiated KHYG-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line"
358:. As of January 2024, KHYG-1 cells have not yet been used in any clinical trial, unlike NK-92 cells.
225:
167:
99:
23:
241:
34:
that are found in blood whose innate function is to kill viral infected cells, cells under stress and
304:
300:
268:
75:
350:. Roos Vincken and Ana Ruiz-Saenz created a protocol to engineer KHYG-1 cell line stably expressing
320:
284:
264:
257:
217:
201:
27:
698:
525:
421:
489:
755:
737:
690:
682:
642:
624:
584:
566:
517:
509:
470:
462:
413:
405:
252:. These attributes of KHYG-1 cells together with their ability to retain their function after
103:
745:
729:
674:
632:
616:
574:
556:
501:
452:
397:
332:
245:
237:
197:
115:
59:
31:
327:. Arwen Stikvoot has investigated the possibility of using KHYG-1 cell line and to create
249:
212:. The expression of these receptors together with constitutively high expression level of
63:
750:
717:
579:
544:
637:
107:
79:
279:
In recent years there have been studies trying to harness KHYG-1 cells as a potential
785:
702:
55:
529:
425:
340:
280:
229:
189:
83:
620:
457:
662:
256:
makes them an interesting cell line as a model to the study of the mechanism of
253:
35:
733:
440:
50:. These cells were derived from the blood of 45-year old female suffering from
678:
505:
324:
296:
292:
221:
193:
174:
741:
686:
628:
570:
513:
466:
409:
545:"Special Issue "New Developments in Natural Killer Cells for Immunotherapy""
441:"KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity"
347:
95:
91:
87:
759:
694:
646:
588:
521:
474:
417:
401:
561:
385:
343:
312:
308:
260:
233:
213:
185:
776:
178:
171:
288:
143:
131:
54:. This cell line has been growing continuously, in the presence of
209:
155:
47:
43:
351:
328:
205:
181:
159:
151:
135:
315:. However, CAR-T cell therapy comes with the danger of causing
331:
CARs in KHYG-1 cells as a therapy option for the treatment of
147:
139:
123:
119:
111:
52:
aggressive
Natural killer cell lymphoblastic leukemia/lymphoma
323:
which would overcome some of the difficulties connected with
40:
Tazuke-Kofukai
Medical Research Institute, Kitano Hospital
303:
as the infusion of these cells has been shown to induce
488:
Suck, G.; Branch, D. R.; Keating, A. (January 2006).
543:Zimmer, Jacques; Jurišić, Vladimir (January 2023).
232:of KHYG-1 cell line. They are also able to secrete
166:and so kills their targets mostly by secretion of
164:antibody dependent cellular cytotoxicity (ADCC)
716:Vincken, Roos; Ruiz-Saenz, Ana (2023-06-16).
335:. Tsutomu Nakazawa created KHYG-1 cells with
299:have been recognized as a promising agent in
8:
339:-specific CAR which inhibited the growth of
228:is thought to be the cause of the increased
216:, which expression is restricted in primary
204:. KHYG-1 cells express activating receptors
134:) and they carry the same point mutation in
494:International Journal of Radiation Biology
749:
636:
578:
560:
456:
356:antibody-dependent cellular cytotoxicity
200:cell line commonly used as a target for
367:
287:to recognize and kill specific human
244:which can afterwards stimulate other
7:
379:
377:
375:
373:
371:
263:and as a potential effector cell in
162:and are therefore unable to perform
142:with the difference that they lack
26:that bears the characteristics of
14:
293:chimeric antigen receptors (CARs)
188:. The KHYG-1 cells show superior
220:, and fully processed cleaved
102:. They also represent similar
1:
74:KHYG-1 cells present similar
777:Cellosaurus entry for KHYG-1
621:10.1097/HS9.0000000000000596
458:10.1016/j.exphem.2005.06.024
170:which contain pore-forming
158:these cells do not express
808:
734:10.1016/j.xpro.2023.102224
309:acute and chronic leukemia
679:10.21873/anticanres.14304
506:10.1080/09553000600649653
317:cytokine release syndrome
301:immune-oncology treatment
30:. NK cells are a type of
196:, which is immortalised
445:Experimental Hematology
281:"Off the Shelf" therapy
177:and apoptosis-inducing
402:10.1038/sj.leu.2401769
307:in some patients with
285:genetically engineered
154:. In the same case as
108:primary leukemia cells
70:Phenotype and function
24:immortalized cell line
16:Immortalized cell line
562:10.3390/cells12111496
98:with large number of
269:cancer immunotherapy
198:myelogenous leukemia
667:Anticancer Research
354:and so capable of
341:glioblastoma cells
275:Clinical relevance
190:cytotoxic activity
451:(10): 1160–1171.
799:
792:Human cell lines
764:
763:
753:
713:
707:
706:
673:(6): 3231–3237.
657:
651:
650:
640:
599:
593:
592:
582:
564:
540:
534:
533:
485:
479:
478:
460:
436:
430:
429:
381:
333:Multiple myeloma
60:cryopreservation
807:
806:
802:
801:
800:
798:
797:
796:
782:
781:
773:
768:
767:
715:
714:
710:
659:
658:
654:
601:
600:
596:
542:
541:
537:
487:
486:
482:
438:
437:
433:
383:
382:
369:
364:
352:FCγRIIIa (CD16)
283:, mostly to be
277:
250:immune reaction
156:NK-92 cell line
140:TP53 (p53) gene
104:immunophenotype
94:, and abundant
72:
64:liquid nitrogen
17:
12:
11:
5:
805:
803:
795:
794:
784:
783:
780:
779:
772:
771:External links
769:
766:
765:
722:STAR Protocols
708:
652:
594:
535:
500:(5): 355–361.
480:
431:
396:(5): 922–930.
366:
365:
363:
360:
291:by expressing
276:
273:
261:leukemogenesis
168:lytic granules
150:but expresses
90:, conspicuous
80:leukemic cells
71:
68:
15:
13:
10:
9:
6:
4:
3:
2:
804:
793:
790:
789:
787:
778:
775:
774:
770:
761:
757:
752:
747:
743:
739:
735:
731:
728:(2): 102224.
727:
723:
719:
712:
709:
704:
700:
696:
692:
688:
684:
680:
676:
672:
668:
664:
656:
653:
648:
644:
639:
634:
630:
626:
622:
618:
614:
610:
606:
598:
595:
590:
586:
581:
576:
572:
568:
563:
558:
554:
550:
546:
539:
536:
531:
527:
523:
519:
515:
511:
507:
503:
499:
495:
491:
484:
481:
476:
472:
468:
464:
459:
454:
450:
446:
442:
435:
432:
427:
423:
419:
415:
411:
407:
403:
399:
395:
391:
387:
380:
378:
376:
374:
372:
368:
361:
359:
357:
353:
349:
345:
342:
338:
334:
330:
326:
322:
318:
314:
310:
306:
302:
298:
294:
290:
286:
282:
274:
272:
270:
266:
262:
259:
255:
251:
247:
243:
239:
235:
231:
227:
223:
219:
215:
211:
207:
203:
199:
195:
191:
187:
183:
180:
176:
173:
169:
165:
161:
157:
153:
149:
145:
141:
137:
133:
129:
125:
121:
117:
113:
109:
105:
101:
97:
93:
89:
85:
81:
77:
69:
67:
65:
61:
57:
53:
49:
45:
41:
37:
33:
29:
25:
21:
725:
721:
711:
670:
666:
655:
612:
608:
597:
555:(11): 1496.
552:
548:
538:
497:
493:
483:
448:
444:
434:
393:
389:
321:CAR-NK cells
278:
246:immune cells
230:cytotoxicity
73:
36:cancer cells
19:
18:
615:(7): e596.
325:CAR-T cells
297:CAR-T cells
254:irradiation
248:and effect
82:with large
32:immune cell
609:HemaSphere
362:References
305:remissions
267:-mediated
214:granzyme M
194:K562 cells
182:granulysin
76:morphology
742:2666-1667
703:219206355
687:0250-7005
629:2572-9241
571:2073-4409
514:0955-3002
467:0301-472X
410:1476-5551
348:apoptosis
234:cytokines
224:in their
138:7 of the
96:cytoplasm
88:chromatin
86:, coarse
66:.
786:Category
760:37071532
751:10323021
695:32487617
647:34131635
589:37296617
580:10252853
530:30502987
522:16782653
475:16219538
426:22938275
418:10803526
390:Leukemia
344:in vitro
337:EGFRvIII
313:lymphoma
236:such as
226:granules
222:perforin
218:NK cells
202:NK cells
192:against
186:granzyme
179:proteins
175:perforin
100:granules
92:nucleoli
28:NK cells
638:8196092
289:cancers
265:NK cell
258:NK cell
172:protein
106:to the
84:nucleus
758:
748:
740:
701:
693:
685:
645:
635:
627:
587:
577:
569:
528:
520:
512:
473:
465:
424:
416:
408:
132:HLA-DR
22:is an
20:KHYG-1
699:S2CID
549:Cells
526:S2CID
422:S2CID
210:NKG2D
206:NKp44
48:Japan
44:Osaka
756:PMID
738:ISSN
691:PMID
683:ISSN
643:PMID
625:ISSN
585:PMID
567:ISSN
518:PMID
510:ISSN
471:PMID
463:ISSN
414:PMID
406:ISSN
346:via
329:CD38
311:and
242:TNFα
240:and
238:IFNγ
208:and
184:and
160:CD16
152:CD33
146:and
144:CD57
136:exon
130:and
128:CD56
116:sCD3
56:IL-2
746:PMC
730:doi
675:doi
633:PMC
617:doi
575:PMC
557:doi
502:doi
453:doi
398:doi
148:CD1
124:CD8
120:CD7
112:CD2
78:to
62:in
788::
754:.
744:.
736:.
724:.
720:.
697:.
689:.
681:.
671:40
669:.
665:.
641:.
631:.
623:.
611:.
607:.
583:.
573:.
565:.
553:12
551:.
547:.
524:.
516:.
508:.
498:82
496:.
492:.
469:.
461:.
449:33
447:.
443:.
420:.
412:.
404:.
394:14
392:.
388:.
370:^
295:.
271:.
126:,
122:,
118:,
114:,
46:,
42:,
762:.
732::
726:4
705:.
677::
649:.
619::
613:5
591:.
559::
532:.
504::
477:.
455::
428:.
400::
110:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.